BACKGROUND: Mycophenolate mofetil (MMF) side effects often prompt dose reduction or discontinuation, and this MMF dose reduction (MDR) can lead to rejection and possibly graft loss. Unfortunately, little is known about what factors might cause or contribute to MDR. Frailty, a measure of physiologic reserve, is emerging as an important, novel domain of risk in kidney transplantation recipients. We hypothesized that frailty, an inflammatory phenotype, might be associated with MDR. METHODS: We measured frailty (shrinking, weakness, exhaustion, low physical activity, and slowed walking speed), other patient and donor characteristics, longitudinal MMF doses, and graft loss in 525 kidney transplantation recipients. Time-to-MDR was quantified using an adjusted Cox proportional hazards model. RESULTS: By 2 years after transplantation, 54% of frail recipients and 45% of nonfrail recipients experienced MDR; by 4 years, incidence was 67% and 51%. Frail recipients were 1.29 times (95% confidence interval [95% CI], 1.01-1.66; P = 0.04) more likely to experience MDR, as were deceased donor recipients (adjusted hazard ratio [aHR], 1.92; 95% CI, 1.44-2.54, P < 0.001) and older adults (age ≥ 65 vs <65; aHR, 1.47; 95% CI, 1.10-1.96, P = 0.01). Mycophenolate mofetil dose reduction was independently associated with a substantially increased risk of death-censored graft loss (aHR, 5.24; 95% CI, 1.97-13.98, P = 0.001). CONCLUSION: A better understanding of risk factors for MMF intolerance might help in planning alternate strategies to maintain adequate immunosuppression and prolong allograft survival.
BACKGROUND:Mycophenolate mofetil (MMF) side effects often prompt dose reduction or discontinuation, and this MMF dose reduction (MDR) can lead to rejection and possibly graft loss. Unfortunately, little is known about what factors might cause or contribute to MDR. Frailty, a measure of physiologic reserve, is emerging as an important, novel domain of risk in kidney transplantation recipients. We hypothesized that frailty, an inflammatory phenotype, might be associated with MDR. METHODS: We measured frailty (shrinking, weakness, exhaustion, low physical activity, and slowed walking speed), other patient and donor characteristics, longitudinal MMF doses, and graft loss in 525 kidney transplantation recipients. Time-to-MDR was quantified using an adjusted Cox proportional hazards model. RESULTS: By 2 years after transplantation, 54% of frail recipients and 45% of nonfrail recipients experienced MDR; by 4 years, incidence was 67% and 51%. Frail recipients were 1.29 times (95% confidence interval [95% CI], 1.01-1.66; P = 0.04) more likely to experience MDR, as were deceased donor recipients (adjusted hazard ratio [aHR], 1.92; 95% CI, 1.44-2.54, P < 0.001) and older adults (age ≥ 65 vs <65; aHR, 1.47; 95% CI, 1.10-1.96, P = 0.01). Mycophenolate mofetil dose reduction was independently associated with a substantially increased risk of death-censored graft loss (aHR, 5.24; 95% CI, 1.97-13.98, P = 0.001). CONCLUSION: A better understanding of risk factors for MMF intolerance might help in planning alternate strategies to maintain adequate immunosuppression and prolong allograft survival.
Authors: Jeremy Walston; Mary Ann McBurnie; Anne Newman; Russell P Tracy; Willem J Kop; Calvin H Hirsch; John Gottdiener; Linda P Fried Journal: Arch Intern Med Date: 2002-11-11
Authors: Seth A Waits; Edward K Kim; Michael N Terjimanian; Lindsay M Tishberg; Calista M Harbaugh; Kyle H Sheetz; Christopher J Sonnenday; June Sullivan; Stewart C Wang; Michael J Englesbe Journal: JAMA Surg Date: 2014-04 Impact factor: 14.766
Authors: Karen Bandeen-Roche; Qian-Li Xue; Luigi Ferrucci; Jeremy Walston; Jack M Guralnik; Paulo Chaves; Scott L Zeger; Linda P Fried Journal: J Gerontol A Biol Sci Med Sci Date: 2006-03 Impact factor: 6.053
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: Ronald P Pelletier; Baris Akin; Mitchell L Henry; Ginny L Bumgardner; Elmahdi A Elkhammas; Amer Rajab; Ronald M Ferguson Journal: Clin Transplant Date: 2003-06 Impact factor: 2.863
Authors: Jon Kobashigawa; Darshana Dadhania; Sangeeta Bhorade; Deborah Adey; Joseph Berger; Geetha Bhat; Marie Budev; Andres Duarte-Rojo; Michael Dunn; Shelley Hall; Meera N Harhay; Kirsten L Johansen; Susan Joseph; Cassie C Kennedy; Evan Kransdorf; Krista L Lentine; Raymond J Lynch; Mara McAdams-DeMarco; Shunji Nagai; Michael Olymbios; Jignesh Patel; Sean Pinney; Joanna Schaenman; Dorry L Segev; Palak Shah; Lianne G Singer; Jonathan P Singer; Christopher Sonnenday; Puneeta Tandon; Elliot Tapper; Stefan G Tullius; Michael Wilson; Martin Zamora; Jennifer C Lai Journal: Am J Transplant Date: 2018-12-22 Impact factor: 8.086
Authors: A J Nastasi; M A McAdams-DeMarco; J Schrack; H Ying; I Olorundare; F Warsame; A Mountford; C E Haugen; M González Fernández; S P Norman; D L Segev Journal: Am J Transplant Date: 2017-08-30 Impact factor: 8.086
Authors: María Pérez Fernández; Patricia Martínez Miguel; Hao Ying; Christine E Haugen; Nadia M Chu; Diego María Rodríguez Puyol; Leocadio Rodríguez-Mañas; Silas P Norman; Jeremy D Walston; Dorry L Segev; Mara A McAdams-DeMarco Journal: Am J Nephrol Date: 2019-01-09 Impact factor: 3.754
Authors: Christine E Haugen; Xun Luo; Courtenay M Holscher; Mary G Bowring; Sandra R DiBrito; Jacqueline Garonzik-Wang; Mara McAdams-DeMarco; Dorry L Segev Journal: Transplantation Date: 2019-11 Impact factor: 4.939
Authors: Alvin G Thomas; Jessica M Ruck; Ashton A Shaffer; Christine E Haugen; Hao Ying; Fatima Warsame; Nadia Chu; Michelle C Carlson; Alden L Gross; Silas P Norman; Dorry L Segev; Mara McAdams-DeMarco Journal: Transplantation Date: 2019-07 Impact factor: 4.939
Authors: Jeremy Walston; Thomas N Robinson; Susan Zieman; Frances McFarland; Christopher R Carpenter; Keri N Althoff; Melissa K Andrew; Caroline S Blaum; Patrick J Brown; Brian Buta; E Wesley Ely; Luigi Ferrucci; Kevin P High; Stephen B Kritchevsky; Kenneth Rockwood; Kenneth E Schmader; Felipe Sierra; Kaycee M Sink; Ravi Varadhan; Arti Hurria Journal: J Am Geriatr Soc Date: 2017-04-19 Impact factor: 5.562
Authors: Nadia M Chu; Alden L Gross; Ashton A Shaffer; Christine E Haugen; Silas P Norman; Qian-Li Xue; A Richey Sharrett; Michelle C Carlson; Karen Bandeen-Roche; Dorry L Segev; Mara A McAdams-DeMarco Journal: J Am Soc Nephrol Date: 2019-01-24 Impact factor: 10.121
Authors: Christine E Haugen; Nadia M Chu; Hao Ying; Fatima Warsame; Courtenay M Holscher; Niraj M Desai; Miranda R Jones; Silas P Norman; Daniel C Brennan; Jacqueline Garonzik-Wang; Jeremy D Walston; Adam W Bingaman; Dorry L Segev; Mara McAdams-DeMarco Journal: Clin J Am Soc Nephrol Date: 2019-03-19 Impact factor: 8.237
Authors: Mara A McAdams-DeMarco; Jingwen Tan; Megan L Salter; Alden Gross; Lucy A Meoni; Bernard G Jaar; Wen-Hong Linda Kao; Rulan S Parekh; Dorry L Segev; Stephen M Sozio Journal: Clin J Am Soc Nephrol Date: 2015-11-16 Impact factor: 8.237